**Specifications Table**TableSubject area*Proteomics and Biochemistry*More specific subject area*Structural biology*Type of data*Tables, figures and X-ray diffraction images*How data was acquired*X-ray macromolecular crystallography;Australian Synchrotron MX1 and MX2 beamlines*Data format*Unprocessed, processed, deposited with crystal packing analyzed.*Experimental factors*Protein crystals soaked and co-crystallized with ligands*Experimental features*Contrast of the different protein crystal packing associated with different inhibitors and/or introduced by soaking or co-crystallization.X-ray diffraction datasets for co-crystallization and soaked-in experiments with the same inhibitor indicate space group changes are independent of method used to introduce the inhibitor.*Data source location*Data collected in Melbourne, Australia.*Data accessibility*The atomic coordinates and observed structure factors are available from Protein Data Bank with accession numbers:*[5BO2](pdb:5BO2){#ir0310}*,*[5BO3](pdb:5BO3){#ir0315}*and*[5BNE](pdb:5BNE){#ir0320}.*The X-ray diffraction image files corresponding to datasets from two experiments are hosted by Mendeley:*[http://dx.doi.org/10.17632/2zrfgv34nb.1](http://http://dx.doi.org/10.17632/2zrfgv34nb.1){#ir0325}[http://dx.doi.org/10.17632/xgn5z8jnr7.1](http://http://dx.doi.org/10.17632/xgn5z8jnr7.1){#ir0330}Related research article*Anthranilate phosphoribosyltransferase: Binding determinants for 5′-phospho-alpha-[d-]{.smallcaps}ribosyl-1′-pyrophosphate (PRPP) and the implications for inhibitor design "in press".*[https://doi.org/10.1016/j.bbapap.2017.08.018](http://https://doi.org/10.1016/j.bbapap.2017.08.018){#ir0335}

**Value of the data**•*Mtb*-AnPRT is a target of interest in developing novel anti-tuberculosis agents. This protein\'s capacity to crystallize thus yield new protein:ligand complexes makes it of interest for structure-based inhibitor design.•Previously *Mtb*-AnPRT:ligand complexes have been found with different space groups (*e.g. P*2~1~, *C*2, *P*2~1~2~1~2, and *P*2~1~2~1~2~1~), generated by using the same crystallization protocol.•*Mtb*-AnPRT:inhibitor complex structures described herein have *C*2 and *P*2~1~ space groups. These structures were solved using X-ray diffraction datasets from protein:ligand crystals generated by streak-seeded with wild-type *P*2~1~2~1~2~1~ crystal.•For one inhibitor, X-ray diffraction datasets are presented for both co-crystallization and soaked crystal experiments. Space group *C*2 occurred in both datasets and indicates the space group change between ligand-free and inhibitor-bound structures are independent of method used to introduce the inhibitor.•X-ray diffraction datasets utilizing different methods of ligand introduction and yielding equivalent protein:ligand structures are typically not made available. These publically available datasets in the context of multiple space groups observed for *Mtb*-AnPRT:ligand structures, and the analysis presented herein, demonstrate that space group changes can be independent of co-crystallization and soaking methods of ligand introduction. This has relevance to academic and industrial researchers who are pursuing structure-based inhibitor design.

1. Data {#s0005}
=======

1.1. Overview {#s0010}
-------------

The experimental and data processing details for 3 new protein:ligand structures of *Mycobacterium tuberculosis* anthranilate phosphoribosyl transferase (*Mtb*-AnPRT) are described herein ([Table 1](#t0005){ref-type="table"}). The protein structures are complexed with *Mtb*-AnPRT inhibitors characterized in [@bib1] and annotated as:•**8k** (2-(2-carboxyphenylamino)-5-(5-phosphonopentyloxy)benzoic acid)•**8j** (2-(2-carboxyphenylamino)-5-(4-phosphonobutoxy)benzoic acid)•**8i** (2-(2-carboxyphenylamino)-5-(3-phosphonopropoxy)benzoic acid)Table 1Summary of *Mtb*-AnPRT structures described herein.Table 1PDB IDLigand IDSolvent contentUnit CellSpace groupResolution (Å)ChainsPDB DOIβ (°)A (Å)B (Å)C (Å)[5BO2](pdb:5BO2){#ir0005}**8i**46%111°9478103*C*22.00A,B[10.2210/pdb5bo2/pdb](http://10.2210/pdb5bo2/pdb){#ir0010}[5BO3](pdb:5BO3){#ir0015}**8j**46%111°9578103*C*21.75A,B[10.2210/pdb5bo3/pdb](http://10.2210/pdb5bo3/pdb){#ir0020}[5BNE](pdb:5BNE){#ir0025}**8k**46%91°7778117*P*2~1~2.15A,B,C D[10.2210/pdb5bne/pdb](http://10.2210/pdb5bne/pdb){#ir0030}

These structures were determined with protein crystallized in presence of imidazole-malate and PEG4000. Crystallization drops seeded with crystal nuclei from a pre-existing *Mtb*-AnPRT crystal generate better crystal morphology for *Mtb*-AnPRT [@bib2]. All new structures presented herein were generated by streak-seeding using wild-type *P*2~1~2~1~2~1~ crystals. Also presented are two X-ray diffraction datasets corresponding to protein crystals either soaked and co-crystallized with the same inhibitor ([Table 2](#t0010){ref-type="table"}).Table 2Crystallization of complexes, along with space group and unit cell from data processing.Table 2PDB IDLigand(s) bound\[Protein\] mg mL^−1^Reservoir conditionCryoprotectant/SoakNotesSpace groupUnit cell[5BO2](pdb:5BO2){#ir0035}**8i :**3.00.2 M imidazole.malate, pH 7.0, 9% PEG40000.2 M imidazole.malate, pH 7.0, 15% PEG4000, 1 mM **8i**Streak seeded; **soaked crystal** for 4 h;*C*294×78×103 Å![](fx1.gif)2 day old crystal**X-ray images available at:**[http://dx.doi.org/10.17632/xgn5z8jnr7.1](http://http://dx.doi.org/10.17632/xgn5z8jnr7.1){#ir0040}*ß*β=111°Not applicable**8i :**3.00.2 M imidazole.malate, pH 7.0, 11% PEG4000, 1 mM **8i**0.2 M imidazole.malate, pH 7.0, 15% PEG4000, 1 mM **8i**Streak seeded; **protein co-crystallized with ligand**;*C*295×78×103 Å![](fx2.gif)2 day old crystalβ=111°**X-ray images available at:**[http://dx.doi.org/10.17632/2zrfgv34nb.1](http://http://dx.doi.org/10.17632/2zrfgv34nb.1){#ir0045}[5BO3](pdb:5BO3){#ir0050}**8j :**3.00.2 M imidazole.malate, pH 7.0, 11% PEG4000,0.2 M imidazole.malate, pH 7.0, 15% PEG4000, 1 mM **8j**Streak seeded; **soaked crystal** for 10 min;*C*295×78×103 Å![](fx3.gif)2 day old crystalβ=111°[5BNE](pdb:5BNE){#ir0055}**8k :**3.10.2 M imidazole.malate, pH 7.0, 15% PEG4000, 1 mM **8k**No cryo used, because crystallization condition contained 15% PEG4000Streak seeded; **protein co-crystallized with ligand**;*P*2~1~77×78×117 Å![](fx4.gif)2 day old crystalβ=91°

Of the previously published structures of *Mtb*-AnPRT, 25 were determined from protein crystallized using this protocol ([Table 3](#t0015){ref-type="table"}). Most of these structures have a ligand bound (*e.g.* inhibitor or substrate) and/or are protein variants with mutations in substrate-binding residues ([Table 3](#t0015){ref-type="table"}). Amongst both cohorts ([Table 1](#t0005){ref-type="table"}, [Table 3](#t0015){ref-type="table"}) several different space groups have been observed, including *P*2~1~, *C*2, *P*2~1~2~1~2, *P*2~1~2~1~2~1~. Amongst the 28 structures referred to in this article ([Table 1](#t0005){ref-type="table"}, [Table 3](#t0015){ref-type="table"}), similar unit cells correspond to each space group.Table 3Space groups, unit cells and other information for previously published *Mtb*-AnPRT structures crystallized in imidazole-malate and PEG4000.Table 3PDB IDRefSolvent contentUnit CellSpace GroupResolution (Å)ChainsNotesPDB DOIβ (°)A (Å)B (Å)C (Å)[3QS8](pdb:3QS8){#ir0060}[@bib2]46%90°7881111*P*2~1~2.00A,B,C,DCo-crystal[10.2210/pdb3qs8/pdb](http://10.2210/pdb3qs8/pdb){#ir0065}[3UU1](pdb:3UU1){#ir0070}[@bib2]45%90°7811180*P*2~1~1.82A,B,C,DCo-crystal[10.2210/pdb3uu1/pdb](http://10.2210/pdb3uu1/pdb){#ir0075}[3R6C](pdb:3R6C){#ir0080}[@bib2]44%110°9478100*C*21.83A,BCo-crystal[10.2210/pdb3r6c/pdb](http://10.2210/pdb3r6c/pdb){#ir0085}[4IJ1](pdb:4IJ1){#ir0090}[@bib5]45%1119578102*C*21.79A,BCo-crystal[10.2210/pdb4ij1/pdb](http://10.2210/pdb4ij1/pdb){#ir0095}[4X58](pdb:4X58){#ir0100}[@bib6]50%1119578101*C*21.75A,BMutant[10.2210/pdb4x58/pdb](http://10.2210/pdb4x58/pdb){#ir0105}[4X59](pdb:4X59){#ir0110}[@bib6]50%1129578102*C*21.80A,BMutant[10.2210/pdb4x59/pdb](http://10.2210/pdb4x59/pdb){#ir0115}[4X5A](pdb:4X5A){#ir0120}[@bib6]49%1129478102*C*21.93A,BMutant[10.2210/pdb4x5a/pdb](http://10.2210/pdb4x5a/pdb){#ir0125}[4X5B](pdb:4X5B){#ir0130}[@bib6]45%1119478100*C*22.47A,BMutant[10.2210/pdb4x5b/pdb](http://10.2210/pdb4x5b/pdb){#ir0135}[4X5C](pdb:4X5C){#ir0140}[@bib6]49%1119478101*C*22.33A,BMutant[10.2210/pdb4x5c/pdb](http://10.2210/pdb4x5c/pdb){#ir0145}[4X5E](pdb:4X5E){#ir0150}[@bib6]50%1109579101*C*21.77A,BMutant[10.2210/pdb4x5e/pdb](http://10.2210/pdb4x5e/pdb){#ir0155}[4GIU](pdb:4GIU){#ir0160}[@bib5]46%901118179*P*2~1~2~1~21.67A,BCo-crystal[10.2210/pdb4giu/pdb](http://10.2210/pdb4giu/pdb){#ir0165}[4GKM](pdb:4GKM){#ir0170}[@bib5]46%901118178*P*2~1~2~1~21.67A,BCo-crystal[10.2210/pdb4gkm/pdb](http://10.2210/pdb4gkm/pdb){#ir0175}[3QR9](pdb:3QR9){#ir0180}[@bib2]57%907992120*P*2~1~2~1~2~1~1.87A,BLigand-free[10.2210/pdb3qr9/pdb](http://10.2210/pdb3qr9/pdb){#ir0185}[4M0R](pdb:4M0R){#ir0190}[@bib5]56%907992120*P*2~1~2~1~2~1~1.96A,BCo-crystal[10.2210/pdb4m0r/pdb](http://10.2210/pdb4m0r/pdb){#ir0195}[4N5V](pdb:4N5V){#ir0200}[@bib7]57%908093121*P*2~1~2~1~2~1~1.90A,BSoak[10.2210/pdb4n5v/pdb](http://10.2210/pdb4n5v/pdb){#ir0205}[4N8Q](pdb:4N8Q){#ir0210}[@bib7]56%908091120*P*2~1~2~1~2~1~2.08A,BSoak[10.2210/pdb4n8q/pdb](http://10.2210/pdb4n8q/pdb){#ir0215}[4N93](pdb:4N93){#ir0220}[@bib7]57%908092121*P*2~1~2~1~2~1~2.03A,BSoak[10.2210/pdb4n93/pdb](http://10.2210/pdb4n93/pdb){#ir0225}[4OWM](pdb:4OWM){#ir0230}[@bib7]60%907992121*P*2~1~2~1~2~1~1.99A,BSoak[10.2210/pdb4owm/pdb](http://10.2210/pdb4owm/pdb){#ir0235}[4OWN](pdb:4OWN){#ir0240}[@bib7]60%908092121*P*2~1~2~1~2~1~2.11A,BSoak[10.2210/pdb4own/pdb](http://10.2210/pdb4own/pdb){#ir0245}[4OWO](pdb:4OWO){#ir0250}[@bib7]60%907992121*P*2~1~2~1~2~1~1.99A,BSoak[10.2210/pdb4owo/pdb](http://10.2210/pdb4owo/pdb){#ir0255}[4OWQ](pdb:4OWQ){#ir0260}[@bib7]61%907992122*P*2~1~2~1~2~1~1.89A,BSoak[10.2210/pdb4owq/pdb](http://10.2210/pdb4owq/pdb){#ir0265}[4OWS](pdb:4OWS){#ir0270}[@bib7]60%908092121*P*2~1~2~1~2~1~2.43A,BSoak[10.2210/pdb4ows/pdb](http://10.2210/pdb4ows/pdb){#ir0275}[4OWU](pdb:4OWU){#ir0280}[@bib7]60%907992121*P*2~1~2~1~2~1~1.89A,BSoak[10.2210/pdb4owu/pdb](http://10.2210/pdb4owu/pdb){#ir0285}[4OWV](pdb:4OWV){#ir0290}[@bib7]60%908092120*P*2~1~2~1~2~1~1.90A,BSoak[10.2210/pdb4owv/pdb](http://10.2210/pdb4owv/pdb){#ir0295}[4X5D](pdb:4X5D){#ir0300}[@bib6]60%908092121*P*2~1~2~1~2~1~2.30A,BMutant[10.2210/pdb4x5d/pdb](http://10.2210/pdb4x5d/pdb){#ir0305}

*P*2~1~2~1~2~1~ is the most common space group for macromolecular structures, and it has been proposed that this is due to its capacity to accommodate repositioning, *i.e.* rotations or translations, within the asymmetric unit, without loss of crystal contacts [@bib3]. The structure of wild-type *Mtb*-AnPRT without ligands (PDB ID: [3QR9](pdb:3QR9){#ir0340}) has previously been solved from protein crystallized in imidazole-malate and PEG4000 in the space group *P*2~1~2~1~2~1~, with two monomers (A, B) in the asymmetric unit, a unit cell of 79×92×120 Å, and 57% solvent content [@bib2].

*Mtb*-AnPRT is a homodimeric protein with an extended "S"-shape, with each subunit containing two domains [@bib4]. In the ligand-free structure, a single dimer (the biological assembly) is found in the asymmetric unit [@bib2]. The two subunits of the dimer are related by a non-crystallographic two-fold symmetry axis (NCS).

1.2. Data for protein complexes with inhibitors {#s0015}
-----------------------------------------------

The three protein:inhibitor complexes (PDB IDs: [5BO2](pdb:5BO2){#ir0345}, [5BO3](pdb:5BO3){#ir0350}, [5BNE](pdb:5BNE){#ir0355}) were solved in the absence of metals and substrate. For these structures, the solvent content has decreased by \~ 10%, the unit cell has changed (*i.e.* dimension(s) decreased by 10--20 Å), and the space group has changed to *P*2~1~ or *C*2, compared to the ligand-free wild-type structure.

In structures of AnPRT from other prokaryote species, domain movement is observed within subunits due to substrate binding and results in compression of the homodimer by 10 Å (*e.g. D*~max~ (maximum distance) changes from 110 to 100 Å [@bib8]). However, superposition of the subunits in the new *Mtb*-AnPRT structures onto the subunits of the ligand-free structure indicates there are no large changes ([Table 4](#t0020){ref-type="table"}; [@bib9]). Additionally, the longest dimension of the *Mtb*-AnPRT dimer is relatively unchanged between the ligand-free protein structure and the protein:ligand complex structures ([Table 4](#t0020){ref-type="table"}; [@bib10]). Thus, the changes in space group are not driven by domain movements within each subunit.Table 4Comparison *Mtb*-AnPRT subunits found in the 3 new structures to ligand-free structure.Table 4RMSD[a](#tbl4fna){ref-type="table-fn"} to chain A-3QR9 (Å)RMSD[a](#tbl4fna){ref-type="table-fn"} to chain B-3QR9 (Å)Longest dimension of dimer (Å)3qr9.pdb:A--0.891093qr9.pdb:B0.89--5bo2.pdb:A0.670.681105bo2.pdb:B0.660.735bo3.pdb:A0.630.531105bo3.pdb:B0.620.735bne.pdb:A0.570.531095bne.pdb:B0.460.745bne.pdb:C0.460.921095bne.pdb:D0.550.60[^2]

The *P*2~1~ structure (PDB ID: [5BNE](pdb:5BNE){#ir0360}) contains an inhibitor annotated as **8k**, and is the third structure of *Mtb*-AnPRT with this space group determined for protein crystallized in the imidazole-malate condition. The increased components in this structure\'s asymmetric unit (chains A-D, vs. chains A and B; [Fig. 1](#f0005){ref-type="fig"}**A**) means that the lower symmetry described by *P*2~1~ can generate equivalent protein content in a similarly-sized unit cell as is observed with structures defined by space groups *P*2~1~2~1~2~1~ or *P*2~1~2~1~2. The ß angle of 91° could be taken to suggest that the space group should be orthorhombic (*e.g. P*2~1~2~1~2 or *P*2~1~2~1~2~1~). Both POINTLESS [@bib11] and ZANUDA [@bib12] indicated that *P*2~1~ was the correct space group for this dataset, however.Fig. 1Understanding changes in crystal packing in the *Mtb*-AnPRT structures with inhibitors. (A) Superposition of the dimer (cartoon) from a *Mtb*-AnPRT:inhibitor structure defined by space group *P*2~1~, PDB ID: 5BNE (chain A, B, C and D in green, cyan, pink and yellow, respectively), onto that of the ligand-free *Mtb*-AnPRT structure (PDB ID: 3QR9 [@bib2]; *P*2~1~2~1~2~1~; chain A and B in dark and light grey, respectively). The figure includes adjacent dimers (ribbons) in equivalent crystal layers (c-b plane in 3QR9 [@bib2] and c-a plane in 5BNE). In (B) the superposition is re-colored with the *Mtb*-AnPRT:inhibitor structure in yellow and the ligand-free *Mtb*-AnPRT structure in dark grey. Arrows highlight the reorientation of dimers relative to each other. (C) Superposition of the dimer (cartoon) from a *Mtb*-AnPRT:inhibitor structure defined by space group *C*2, PDB ID: 5BO2 (marine blue) onto that of the ligand-free *Mtb*-AnPRT structure (PDB ID: 3QR9 [@bib2]; *P*2~1~2~1~2~1~; dark grey). In (D) superpositions in panels B-C are combined.Fig. 1

\(A\) Superposition of the dimer (cartoon) from a *Mtb*-AnPRT:inhibitor structure defined by space group *P*2~1~, PDB ID: [5BNE](pdb:5BNE){#ir0365} (chain A, B, C and D in green, cyan, pink and yellow, respectively), onto that of the ligand-free *Mtb*-AnPRT structure (PDB ID: [3QR9](pdb:3QR9){#ir0370} [@bib2]; *P*2~1~2~1~2~1~; chain A and B in dark and light grey, respectively). The figure includes adjacent dimers (ribbons) in equivalent crystal layers (c-b plane in 3QR9 [@bib2] and c-a plane in 5BNE). In (B) the superposition is re-colored with the *Mtb*-AnPRT:inhibitor structure in yellow and the ligand-free *Mtb*-AnPRT structure in dark grey. Arrows highlight the reorientation of dimers relative to each other. (C) Superposition of the dimer (cartoon) from a *Mtb*-AnPRT:inhibitor structure defined by space group *C*2, PDB ID: [5BO2](pdb:5BO2){#ir0375} (marine blue) onto that of the ligand-free *Mtb*-AnPRT structure (PDB ID: [3QR9](pdb:3QR9){#ir0380} [@bib2]; *P*2~1~2~1~2~1~; dark grey). In (D) superpositions in panels B-C are combined.

Structural superposition of the dimers from *Mtb*-AnPRT:inhibitor structures (PDB ID: [5BNE](pdb:5BNE){#ir0385} and [5BO2](pdb:5BO2){#ir0390}) onto the dimer present in the *P*2~1~2~1~2~1~ ligand-free *Mtb*-AnPRT structure (PDB ID: [3QR9](pdb:3QR9){#ir0395} [@bib2]) revealed a reorientation of the protein dimers relative to each other ([Fig. 1](#f0005){ref-type="fig"}**B and C**). The combination of these superpositions ([Fig. 1](#f0005){ref-type="fig"}**D**) indicates that the lattice in the *P*2~1~ structure corresponds to an intermediate position between the lattice observed for *P*2~1~2~1~2~1~ and *C*2 structures. We propose the subunits that are related by crystallographic symmetry elements in the *P*2~1~2~1~2~1~ structures are related by pseudosymmetry elements in the *P*2~1~ structure. Pseudosymmetry occurs where a non-crystallographic symmetry element within the asymmetric unit is close to a crystallographic symmetry operators [@bib13]. Thus, the *P*2~1~ space group has been correctly assigned, even though the unit cell has a β of approximately 90 °.

The generation of the protein: inhibitor structures, involved experiments, with all three inhibitors, using both co-crystallization and soaking-in methods. The structures deposited on the PDB correspond to those where the clearest density was observed for the inhibitor (*i.e.* modelled with full occupancy; [Fig. 2](#f0010){ref-type="fig"}). In [Table 5](#t0025){ref-type="table"} there are data statistics corresponding to *Mtb*-AnPRT co-crystallized with inhibitor **8i**. In [Table 6](#t0030){ref-type="table"} are data statistics corresponding to inhibitor **8i** soaked into a wild-type ligand-free *Mtb*-APRT crystal. In both cases, with no manual intervention, the datasets processed in XDS [@bib15] and AIMLESS [@bib11] as space group *C*2. Thus, in this study, there no correlation was found between space group type and the method by which the ligand was introduced (*i.e.* soaking vs. co-crystallization).Fig. 2Omit and fitted map for inhibitors bound in *Mtb*-AnPRT structures. The *F*~o~-*F*~c~ map calculated (green, contoured at 3 σ) prior to the addition of ligands to the model for A) 8k, B) 8j and C) 8i (PDB entries 5BNE, 5BO3 and 5BO2, respectively). The 2*F*~o~-*F*~c~ map calculated (blue, contoured at 1 σ) after final refinement, with model including the ligands for D) 8k (black), E) 8j (green) and F) 8i (pink).Fig. 2Table 5Statistics for dataset of *Mtb*-AnPRT co-crystallized with inhibitor 8i.Table 5**Data collection**AnPRT complexed with**8i**Space group*C*2Cell dimensions a, b, c (Å)94.6, 78.1, 102.8 β (deg)110.9Unique reflections[a](#tbl5fna){ref-type="table-fn"}387946 (24179)Resolution range (Å)[a](#tbl5fna){ref-type="table-fn"}48-1.95 (2.00-1.95)*R*~merge~[a](#tbl5fna){ref-type="table-fn"}0.138 (1.237)*R*~p.i.m.~[a](#tbl5fna){ref-type="table-fn"}0.054 (0.488)Mean *I/σ*(I)[a](#tbl5fna){ref-type="table-fn"}9.9 (1.5)CC~1/2~[a](#tbl5fna){ref-type="table-fn"}0.997 (0.679)Completeness (%)[a](#tbl5fna){ref-type="table-fn"}99.6 (94.0)Redundancy[a](#tbl5fna){ref-type="table-fn"}7.6 (7.1)Wilson B factor20.5[^3][^4]Table 6Data and refinement statistics for AnPRT complexes with inhibitors.Table 6**Data collection**AnPRT complexed with**8i8j8k**PDB code5BO25BO35BNESpace group*C*2*C*2*P*2~1~Cell dimensions a, b, c (Å)94.5, 78.0, 102.995.0, 78.1, 102.677.3, 78.4, 117.2 β (deg)111.0111.190.7Unique reflections[a](#tbl6fna){ref-type="table-fn"}47170 (3415)68993 (3669)75079 (4387)Resolution range (Å)[a](#tbl6fna){ref-type="table-fn"}47-2.00 (2.05-2.00)48-1.75 (1.78-1.75)47-2.15 (2.19-2.15)*R*~merge~[a](#tbl6fna){ref-type="table-fn"}0.121 (0.856)0.121 (1.762)0.111 (0.711)*R*~p.i.m.~[a](#tbl6fna){ref-type="table-fn"}0.076 (0.564)0.046 (0.688)0.073 (0.477)Mean *I/σ*(I)[a](#tbl6fna){ref-type="table-fn"}8.5 (1.5)13.3 (1.2)6.9 (1.5)CC~1/2~[a](#tbl6fna){ref-type="table-fn"}0.993 (0.564)0.998 (0.465)0.993 (0.502)Completeness (%)[a](#tbl6fna){ref-type="table-fn"}99.8 (97.7)97.8 (93.7)98.4 (77.3)Redundancy[a](#tbl6fna){ref-type="table-fn"}3.4 (3.3)7.8 (7.4)3.0 (2.9)Wilson B factor15.116.321.4**Refinement**Atoms, B factor (Å^2^)[b](#tbl6fnb){ref-type="table-fn"}Protein4788, 25.84746, 24.69280, 29.0Solvent352, 29.7402, 29.2353, 29.5Ligands79, 33.266, 26.6107, 30.6*R*~work~/*R*~free~ (%/%)[a](#tbl6fna){ref-type="table-fn"}^*,*^[c](#tbl6fnc){ref-type="table-fn"}0.192/0.2320.206/0.2400.207/0.235(0.276/0.324)(0.319/0.336)(0.284/0.332)Ramachandran outliers (%)0.310.160.31R.m.s.d. of Bond lengths (Å)[d](#tbl6fnd){ref-type="table-fn"}0.0030.0050.003 Bond angles (°)[d](#tbl6fnd){ref-type="table-fn"}0.7740.8990.745[^5][^6][^7][^8]

2. Experimental design, materials and methods {#s0020}
=============================================

2.1. Materials {#s0025}
--------------

Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich, Scharlau, or Pure Science. The purification of *Mtb*-AnPRT, as well as the synthesis and biochemical characterization of its inhibitors annotated as **8i**, **8j** and **8k** ([Table 2](#t0010){ref-type="table"}), are outlined in the article entitled "*Anthranilate phosphoribosyltransferase: Binding determinants for 5′-phospho-alpha-[d-]{.smallcaps}ribosyl-1′-pyrophosphate (PRPP) and the implications for inhibitor design"* [@bib1].

2.2. Crystallization {#s0030}
--------------------

Crystals of *Mtb*-AnPRT were obtained in hanging drops of 1--2 μL protein solution (3.0--3.1 mg mL^−1^ in final storage buffer) with the equivalent amount of reservoir solution in a fine screen of 0.2 M imidazole-malate pH 7.0--8.5, 5--15% polyethylene glycol (PEG) 4000, as previously reported [@bib2]. Complexes were prepared either by co-crystallization or by soaking with ligands (details in [Table 2](#t0010){ref-type="table"}). The crystallization drops were seeded from previously formed crystals of *Mtb*-AnPRT, by streak seeding using a cat whisker. Data collection occurred within a few days after crystallization. In preparation for data collection, crystals were typically soaked in a reservoir solution containing cryoprotectant 15% PEG4000 and appropriate ligands (details in [Table 2](#t0010){ref-type="table"}), before being flash-cooled in liquid nitrogen.

2.3. Data collection, structure solution and refinement {#s0035}
-------------------------------------------------------

Data were collected at the Australian Synchrotron, Beamlines MX1 and MX2 at 110 K. The crystals of the *Mtb*-AnPRT complexes diffracted to a maximum resolution that varied between 1.75 and 2.15 Å. X-ray diffraction spots were indexed and integrated with XDS [@bib15] and scaled with AIMLESS [@bib11]. The high resolution cut-off was determined based on a correlation coefficient (CC~1/2~) [@bib16] exceeding 0.5, with mean *I/σ* between 1 and 1.5, and a *R*~p.i.m.~ of 0.7 or less, as calculated by AIMLESS [@bib11]. *R*~p.i.m.~ is defined as ∑*hkl* \[1/(n−1)\]×*R*~merge~, with *R*~merge~ defined as ∑*hkl*\|*I*(*hkl*)-\<*I*(*hkl*)\>\|/∑*hkl*\<*I*(*hkl*)\>, where \<*I*(*hkl*)\> is the mean of symmetry-equivalent reflections of *I*(*hkl*) [@bib17]. Data and refinement statistics are given in [Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"}.

*Mtb*-AnPRT (chain A of 3QR9 [@bib2]), without solvent or ligands, and with loops I and II removed, was used as the search model for structure determination by molecular replacement using Phaser [@bib18]. Refinement and model building was performed with COOT [@bib19], Refmac5 [@bib20], and PHENIX [@bib21]. After positioning waters, omit maps were examined ([Fig. 2](#f0010){ref-type="fig"}) and ligands placed, with subsequent refinement including restraints for the ligands generated by phenix.elbow [@bib21]. Restraints on protein bond lengths and angles were based on the ideal values of Engh and Huber [@bib14] and model quality was assessed using MolProbity [@bib22]. Figures illustrating structural details were prepared using PyMOL.

The *F*~o~-*F*~c~ map calculated (green, contoured at 3 σ) prior to the addition of ligands to the model for A) **8k**, B) **8j** and C) **8i** (PDB entries [5BNE](pdb:5BNE){#ir0400}, [5BO3](pdb:5BO3){#ir0405} and [5BO2](pdb:5BO2){#ir0410}, respectively). The 2*F*~o~-*F*~c~ map calculated (blue, contoured at 1 σ) after final refinement, with model including the ligands for D) **8k** (black), E) **8j** (green) and F) **8i** (pink).
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Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2017.10.051](http://dx.doi.org/10.1016/j.dib.2017.10.051){#ir0420}.

[^1]: Present address: Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1HH, United Kingdom

[^2]: Root mean standard difference (RMSD) between the C~alpha~ atoms

[^3]: ^b^ The average atomic temperature factor. ^c^*R*~work~=(\|*F*~obs~\| - \|*F*~calc~\|)/\|*F*~obs~\| and *R*~free~=∑T (\|*F*~obs~\| - \|*F*~calc~\|)/∑T \|F~obs~\|, where T is a test dataset of 5% of the total reflections randomly chosen and set aside before refinement. ^d^ RMSD from ideal geometry values from [@bib14][@bib14].

[^4]: Outer resolution shell is shown in parentheses.

[^5]: Outer resolution shell is shown in parentheses.

[^6]: The average atomic temperature factor.

[^7]: *R*~work~=(\|*F*~obs~\| - \|*F*~calc~\|)/\|*F*~obs~\| and *R*~free~=∑T (\|*F*~obs~\| - \|*F*~calc~\|)/∑T \|F~obs~\|, where T is a test dataset of 5% of the total reflections randomly chosen and set aside before refinement.

[^8]: RMSD from ideal geometry values from [@bib14][@bib14].
